Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial

Overview of attention for article published in Cancer (0008543X), October 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

blogs: 1 blog
twitter: 43 X users

facebook: 1 Facebook page
guideline: 3 clinical guideline sources

Readers on

mendeley: 53 Mendeley

So far, Altmetric has seen 56 X posts from 43 X users, with an upper bound of 190,046 followers.

RT @VivekSubbiah: Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: Sarculator‐based risk stratification of ISG‐STS 1001 randomiz…

RT @AnkitmanglaMD: Incorporating neoadjuvant approaches in high risk STS. @LukeRothermel @UHSurgeryRes

RT @DrOrtizCruz: Great new paper regard neoadyuvant #chemotherapy in high risk #sarcomas #sarcoma. Outstanding authors!!. @RuberInter @MDAn…

Incorporating neoadjuvant approaches in high risk STS. @LukeRothermel @UHSurgeryRes

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 52 additional X posts.